SCHEMBL17711642

SCHEMBL17711642

CCS(=O)(=O)c1ccc(C(CC(=O)OC)NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
LMNA P02545 2/20 0.43
PKM P14618 2/20 0.43
HPGD P15428 2/20 0.43
TSHR P16473 2/20 0.43
HTT P42858 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HSD17B10 Q99714 2/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
AGTR1 P30556 1/20 0.43
RAB9A P51151 1/20 0.43
RORC P51449 4/20 0.43
MMP13 P45452 2/20 0.43
CA2 P00918 5/20 0.41
CA1 P00915 2/20 0.41
CA9 Q16790 2/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41
PTPRB P23467 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17711643 1.00 ALDH1A1 (0.43) ALDH1A1LMNAPKMHPGDTSHR
SCHEMBL30075100 0.90 ALDH1A1 (0.40) ALDH1A1LMNAPKMHPGDTSHR
SCHEMBL19183235 0.89 MMP13 (0.46) ALDH1A1LMNAPKMHPGDTSHR
SCHEMBL19183236 0.89 MMP13 (0.46) ALDH1A1LMNAPKMHPGDTSHR
SCHEMBL30075155 0.88 CA2 (0.43) ALDH1A1LMNAPKMHPGDTSHR
SCHEMBL28620442 0.88 CA2 (0.43) ALDH1A1LMNAPKMHPGDTSHR
SCHEMBL29287122 0.86 RORC (0.44) ALDH1A1LMNAPKMHPGDTSHR
SCHEMBL20634741 0.86 RORC (0.44) ALDH1A1LMNAPKMHPGDTSHR
SCHEMBL17722792 0.86 RORC (0.45) ALDH1A1LMNAPKMHPGDTSHR
SCHEMBL28619571 0.86 RORC (0.45) ALDH1A1LMNAPKMHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3939974-A1 MODULATORS OF ROR-GAMMA Vitae Pharmaceuticals, LLC (US) 2022-01-19 EP disclosed
EP-3408268-B1 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA VITAE PHARMACEUTICALS LLC (US) 2021-08-04 EP disclosed
CN-113072542-A ROR gamma t inhibitor and preparation method and application thereof 广东东阳光药业有限公司 2021-07-06 CN disclosed
US-9845308-B2 Isoindoline inhibitors of ROR-gamma VITAE PHARMACEUTICALS, INC. (US) 2017-12-19 US disclosed
WO-2017132432-A1 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA VITAE PHARMACEUTICALS, INC. (US) 2017-08-03 WO disclosed
US-20160122318-A1 ISOINDOLINE INHIBITORS OF ROR-GAMMA VITAE PHARMACEUTICALS, LLC 2016-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122318-A1 ISOINDOLINE INHIBITORS OF ROR-GAMMA RORC, RORB, RORA ALDH1A1 243/4885LMNA 4433/4885PKM 2945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.